Evidence map›Paper›PMID 33307038›Full record

ArticleThe American journal of pathology2021

An RGDKGE-Containing Cryptic Collagen Fragment Regulates Phosphorylation of Large Tumor Suppressor Kinase-1 and Controls Ovarian Tumor Growth by a Yes-Associated Protein-Dependent Mechanism.

XiangHua Han, Jennifer M Caron, Christine W Lary, Pradeep Sathyanarayana, Calvin Vary, Peter C Brooks

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

XiangHua HanMaine Medical Center Research Institute, Center for Molecular Medicine, Scarborough, Maine.
Jennifer M CaronMaine Medical Center Research Institute, Center for Molecular Medicine, Scarborough, Maine.
Christine W LaryMaine Medical Center Research Institute, Center for Molecular Medicine, Scarborough, Maine.
Pradeep SathyanarayanaMaine Medical Center Research Institute, Center for Molecular Medicine, Scarborough, Maine.
Calvin VaryMaine Medical Center Research Institute, Center for Molecular Medicine, Scarborough, Maine.
Peter C BrooksMaine Medical Center Research Institute, Center for Molecular Medicine, Scarborough, Maine. Electronic address: brookp1@mmc.org.
Maine Medical Center Research Institute · USMaine Medical Center · US

Funding

Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Kimberly Luebbers · 2017 to 2026
$51.6M
The role of night shift work in metabolic disorders during and after pregnancyP20GM121301 · NIGMS · MAINEHEALTH · PI CLIFFORD JAMES ROSEN · 2017 to 2026
$25.1M
Role of the macrophage derived XL313 epitope in angiogenesis and tumor growthR01CA196739 · NCI · MAINEHEALTH · PI BROOKS, PETER C. · 2017 to 2021
$1.8M
NCI NIH HHS R01 CA196739NIGMS NIH HHS P20 GM121301NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

The growth and spread of malignant tumors, such as ovarian carcinomas, are governed in part by complex interconnected signaling cascades occurring between stromal and tumor cells. These reciprocal cross-talk signaling networks operating within the local tissue microenvironment may enhance malignant tumor progression. Understanding how novel bioactive molecules generated within the tumor microenvironment regulate signaling pathways in distinct cellular compartments is critical for the development of more effective treatment paradigms. Herein, we provide evidence that blocking cellular interactions with an RGDKGE-containing collagen peptide that selectively binds integrin β3 on ovarian tumor cells enhances the phosphorylation of the hippo effector kinase large tumor suppressor kinase-1 and reduces nuclear accumulation of yes-associated protein and its target gene c-Myc. Selectively targeting this RGDKGE-containing collagen fragment inhibited ovarian tumor growth and the development of ascites fluid in vivo. These findings suggest that this bioactive collagen fragment may represent a previously unknown regulator of the hippo effector kinase large tumor suppressor kinase-1 and regulate ovarian tumor growth by a yes-associated protein-dependent mechanism. Taken together, these data not only provide new mechanistic insight into how a unique collagen fragment may regulate ovarian cancer, but in addition may help provide a useful new alternative strategy to control ovarian tumor progression based on selectively disrupting a previously unappreciated signaling cascade.

Indexed as

AnimalsApoptosisBiomarkers, TumorCell ProliferationCollagenFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred C57BLMice, NudeOvarian NeoplasmsPeptide FragmentsPhosphorylationProtein Serine-Threonine KinasesProto-Oncogene Proteins c-yesBiomarkers, TumorCollagenLATS1 protein, humanPeptide FragmentsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-yesYES1 protein, human

Identifiers

PMID33307038
PMCPMC7927278
OpenAlexW3113124733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.